Welcome to our dedicated page for Dolby Laboratories SEC filings (Ticker: DLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dolby Laboratories, Inc. (NYSE: DLB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports, quarterly updates, proxy materials, and current reports on material events. As a Delaware corporation with Class A common stock listed on the New York Stock Exchange, Dolby files documents such as Form 10-K, Form 10-Q, Form 8-K, and the Definitive Proxy Statement (DEF 14A) with the U.S. Securities and Exchange Commission.
Dolby’s filings offer detailed insight into its licensing-focused business model, which centers on technologies like Dolby Atmos, Dolby Vision, Dolby Cinema, Dolby OptiView, and related audio and imaging intellectual property. In its proxy statement and other filings, the company discusses its single reportable segment, the importance of royalty-based revenue, and the role of cinema hardware and premium cinema technologies in its overall revenue mix.
Through current reports on Form 8-K, Dolby discloses financial results, dividends, and executive compensation plans. These filings cover quarterly and annual revenue, net income, non-GAAP metrics, and capital return actions such as cash dividends on Class A and Class B common stock. They also describe executive bonus plans that tie incentive payouts to non-GAAP operating income, revenue, and other performance metrics.
The Definitive Proxy Statement (DEF 14A) provides information on corporate governance and executive compensation, including proposals for the election of directors, advisory votes on named executive officer compensation, and ratification of the independent registered public accounting firm. It also summarizes non-GAAP financial measures and includes reconciliations to GAAP in appendices.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, highlight key figures and themes, and make it easier to understand Dolby’s financial condition, risk disclosures, and governance practices. Investors can use this page to follow Dolby’s official communications to regulators, monitor dividend and capital allocation decisions, and review the frameworks used to evaluate and reward the company’s leadership.
Dorchester Minerals, L.P. (DLB) filing a Form 144 reports a proposed sale of 7,666 shares resulting from a stock option exercise dated 05/05/2026, and discloses prior sales of 4,688 shares on 05/04/2026 for $274,083.92. The filing identifies the broker as Morgan Stanley Smith Barney LLC.
Morgan Stanley Smith Barney LLC filed a Form 144 disclosing an intended sale of 4,688 shares of common stock of DLB. The filing lists separate lots: 2,661 restricted shares, 280 restricted shares, and 1,747 performance shares. The filing notes NYSE and a filing date of 05/04/2026.
Dolby Laboratories reported solid results for the fiscal quarter ended March 27, 2026, with modest growth and continued cash returns to shareholders. Total revenue rose to $395.6 million from $369.6 million, led by licensing revenue of $372.2 million, or 94% of sales. Net income attributable to Dolby increased to $94.9 million, with diluted EPS of $0.99 versus $0.94 a year earlier.
Year-to-date, revenue reached $742.3 million, while net income declined to $148.2 million from $159.6 million as operating expenses and restructuring charges remained elevated. Dolby generated $147.3 million of operating cash flow year-to-date, ended the quarter with $594.3 million in cash and cash equivalents, and continued its capital return program with $135.0 million of share repurchases and quarterly dividends of $0.36 per share.
Dolby Laboratories reported modestly higher results for its second quarter of fiscal 2026 and maintained its dividend. Total revenue was $395.6 million, up from $369.6 million a year earlier, driven mainly by licensing revenue of $372.2 million. GAAP net income attributable to Dolby was $94.9 million, compared with $91.8 million, and GAAP diluted EPS was $0.99. Non-GAAP net income reached $131.3 million with non-GAAP diluted EPS of $1.37. Year-to-date operating cash flow was $147.3 million. The company declared a quarterly cash dividend of $0.36 per share on Class A and B stock, payable on May 20, 2026 to stockholders of record on May 12, 2026. For fiscal 2026, Dolby targets a GAAP gross margin of 88%, non-GAAP gross margin of 90%, GAAP operating margin around 21% and non-GAAP operating margin around 34%, with GAAP diluted EPS guidance of $2.66–$2.81 and non-GAAP diluted EPS of $4.30–$4.45.
Dolby Laboratories Inc ownership filing shows Vanguard Capital Management reports beneficial ownership of 3,193,409 shares of Common Stock, representing 5.24% of the class. The filing lists 467,034 shares with sole voting power and notes dispositive power over all 3,193,409 shares.
The statement attributes holdings to Vanguard Capital Management and affiliated business divisions and is signed by Vanguard's Head of Global Fund Administration on 04/29/2026.
Vanguard Portfolio Management reported beneficial ownership of 5,019,900 shares of Dolby Laboratories Inc. common stock, equal to 8.24% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 5,019,900 shares and sole voting power for 49,076 shares. The statement clarifies these holdings reflect securities managed across Vanguard affiliates and funds.
The Bank of New York Mellon Corporation amended its Schedule 13G to report passive ownership stakes in Dolby Laboratories, Inc. Class A common stock. The amendment lists specific subsidiaries with their reported beneficial holdings and percentage of the class, including The Bank of New York Mellon with 4,499,820 shares (7.4%), BNY Mellon IHC, LLC with 3,791,098 shares (6.2%), MBC Investments Corp with 3,791,098 shares (6.2%), and Newton Investment Management North America, LLC with 3,275,399 shares (5.4%).
The filing states these holdings are held in various fiduciary capacities by BNY Mellon and its subsidiaries; no single third party is reported as having more than 5% beneficial interest in the securities for purposes of Item 6.
Dolby Laboratories director Emily Rollins reported an open-market sale of 1,000 shares of Class A common stock at $60.08 per share on April 1, 2026. After this transaction, she directly holds 12,541 shares of Class A common stock.
Her post-transaction holdings include 3,908 shares underlying restricted stock units that remain subject to forfeiture until they vest, meaning part of her reported position is tied to future service or performance conditions rather than fully vested stock.
DLB submitted a Rule 144 notice reporting proposed sales of common stock totaling 1,000 shares. The filing lists 245 shares dated 02/06/2023 and 755 shares dated 02/05/2024 as restricted stock being sold through Morgan Stanley Smith Barney LLC. The securities are listed on NYSE.
The Vanguard Group filed Amendment No. 14 to a Schedule 13G/A reporting Dolby Laboratories Inc. common stock and states it beneficially owns 0 shares representing 0% of the class.
The filing explains an internal realignment effective January 12, 2026, that disaggregated certain Vanguard subsidiaries and business divisions for reporting under SEC Release No. 34-39538; the filing is signed by Ashley Grim, Head of Global Fund Administration.